Archive for August, 2026

๐“๐ก๐ž ๐€๐‹๐’ ๐๐ซ๐ฎ๐  ๐ ๐ซ๐š๐ฏ๐ž๐ฒ๐š๐ซ๐ ๐ข๐ฌ ๐œ๐ซ๐จ๐ฐ๐๐ž๐

Posted by Michael A. S. Guth on August 5th, 2026

Since 1995, when the FDA approved riluzole for amyotrophic lateral sclerosis (ALS) โ€“ offering a median survival extension measured in weeks โ€“ more than 60 compounds have advanced to clinical evaluation, with the overwhelming majority failing to demonstrate efficacy.(p1) It is worth distinguishing, within that graveyard, between uninformative โ€˜failedโ€™ trials that lacked biomarkers and left […]

Posted in Featured, Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing No Comments »
Read More »

๐“๐š๐ซ๐ ๐ž๐ญ๐ข๐ง๐  ๐“๐ƒ๐-๐Ÿ’๐Ÿ‘ ๐ข๐ง ๐€๐‹๐’: ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐ก๐ฎ๐ซ๐๐ฅ๐ž๐ฌ, ๐ญ๐ซ๐ข๐š๐ฅ ๐๐ž๐ฌ๐ข๐ ๐ง ๐๐ž๐Ÿ๐ข๐œ๐ข๐ž๐ง๐œ๐ข๐ž๐ฌ, ๐š๐ง๐ ๐ญ๐ก๐ž ๐œ๐š๐ฎ๐ฌ๐š๐ฅ ๐ž๐ฏ๐ข๐๐ž๐ง๐œ๐ž ๐ ๐š๐ฉ ๐Ÿ๐จ๐ซ ๐‚๐“๐ฑ๐Ÿ๐ŸŽ๐ŸŽ๐ŸŽ

Posted by Michael A. S. Guth on August 5th, 2026

๐“๐š๐ซ๐ ๐ž๐ญ๐ข๐ง๐  ๐“๐ƒ๐-๐Ÿ’๐Ÿ‘ ๐ข๐ง ๐€๐‹๐’: ๐‘๐ž๐ ๐ฎ๐ฅ๐š๐ญ๐จ๐ซ๐ฒ ๐ก๐ฎ๐ซ๐๐ฅ๐ž๐ฌ, ๐ญ๐ซ๐ข๐š๐ฅ ๐๐ž๐ฌ๐ข๐ ๐ง ๐๐ž๐Ÿ๐ข๐œ๐ข๐ž๐ง๐œ๐ข๐ž๐ฌ, ๐š๐ง๐ ๐ญ๐ก๐ž ๐œ๐š๐ฎ๐ฌ๐š๐ฅ ๐ž๐ฏ๐ข๐๐ž๐ง๐œ๐ž ๐ ๐š๐ฉ ๐Ÿ๐จ๐ซ ๐‚๐“๐ฑ๐Ÿ๐ŸŽ๐ŸŽ๐ŸŽ, Michael A.S. Guth, Drug Discovery Today, Volume 31, Issue 5, 2026, 104752, ISSN 1359-6446, https://doi.org/10.1016/j.drudis.2026.104752. https://www.sciencedirect.com/science/article/pii/S1359644626001571 Highlights โ€ข Over 60 amyotrophic lateral sclerosis (ALS) drug failures since 1995 underscore a persistent trial graveyard. โ€ข CTX1000โ€™s degron fusion selectively clears […]

Posted in Aging Adults, Pharma and Medical Device, Regulatory Medical Writing No Comments »
Read More »